3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Sigma Healthcare Ltd (ASX: SIG) share price could be a really appealing investment for a number of reasons.

The business may still have the name of Sigma Healthcare, but the biggest profit generator within the business is now Chemist Warehouse, which is the biggest pharmacy business in Australia. It also owns Amcal, Discount Drug Stores, and Optometrist Warehouse.

Following the merger earlier this year between Sigma Healthcare and Chemist Warehouse, I think the business is a compelling opportunity. Let's get into why I'm optimistic.

A senior pharmacist talks to a customer at the counter in a shop.

Image source: Getty Images

Defensive earnings

With the current uncertainty because of global events, some investors may be drawn to the defensive nature of the business.

I think most Chemist Warehouse customers will continue shopping at the stores (or online), whether the world is going through geopolitical uncertainty or a downturn.

Having defensive, dependable earnings in the current circumstances is appealing because of how consistent the profit can be, which could help support the Sigma Healthcare share price.

When a defensive business can grow earnings, it becomes even more attractive.

Strong core growth

Sigma says that Chemist Warehouse has a proven track record of sustained strong domestic growth and it's under-penetrated in certain states, providing it with organic growth opportunities.

Management think annual new store openings for Chemist Warehouse in the short to medium-term will be in line with the past five years. The company also believes there is an opportunity to expand the Amcal and Discount Drug Store networks through an 'enhanced retail offering.'

The business reported that its normalised operating profit (EBIT) for the group was around 36% for the nine months to 31 March 2025, which is an excellent growth rate to help power the Sigma Healthcare share price higher if that continues.

Domestically, the business has potential and there's also significant potential overseas.

International growth

The business currently has 56 stores in New Zealand and has intentions to grow in a number of other countries. At the end of Chemist warehouse's first half of FY25, it had 12 locations in Ireland, 11 locations China, and two locations in Dubai.

Chemist Warehouse says that the New Zealand experience demonstrates the transportability and acceptance of the Chemist Warehouse brand and value proposition in new geographies.

It's taking a "measured" approach to expansion in current geographies and it's evaluating opportunities to expand into new geographies. Overall, the international segment could play an important part in the performance of the Sigma Healthcare share price in the coming years and could allow the business to become much bigger.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why are Telix Pharmaceuticals shares charging higher today?

A key approval is good news for this drug developer.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

Telix Pharmaceuticals’ US FDA approval for Pixclara is a first for glioma imaging, expanding its precision medicine offerings.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

CSL shares just fell 5% after a strong rally. Is the recovery losing steam?

Can CSL’s improving outlook justify its higher share price?

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Healthcare Shares

Higher or lower: Where are CSL shares going next?

The biotech giant has been on a tear. Is it too late to invest? Let's find out.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

ASX healthcare shares are 39% higher since June. Are you missing out?

Healthcare stocks endured a long slump before the sector pivoted three months ago.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

EchoIQ shares just crashed 48%. What happens now?

One regulatory letter, half the market cap.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

CSL shares are up 90%. How much higher can they go?

CSL’s recovery could deliver more upside or another sharp reversal.

Read more »

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

Why has this ASX biotech fallen nearly 50% today?

A knockback for a key approval has rocked this company.

Read more »